We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Cancer/Oncology
-
1. Blood cleansing as immunotherapy: testing a novel cancer vaccine strategy- Prof. Raymond Goodrich
-
3. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
4. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Dr. Sebastian Kobold
-
5. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
6. Pediatric cancer testing
- Prof. Joshua Schiffman
- Neurology/Neuroscience
-
7. Risdiplam for prenatal therapy of spinal muscular atrophy- Dr. Richard Finkel
-
10. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
11. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
- Cardiovascular
-
12. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
- Respiratory Diseases
-
14. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
- Immunology & Inflammation
-
15. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
16. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
- Infectious Diseases/Microbiology
-
17. Combating the HIV epidemic
- Prof. William Blattner
-
18. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
- Clinical Practice
-
20. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
-
21. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
22. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
23. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
24. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
Topics Covered
- An overview of CAR-T cell therapy
- Introduction to the mode of action of CAR-T cell therapy
- Differences between CAR-T and TCR-T therapies
- Resistance mechanisms to CAR-T cell therapy
Biography
Dr. Kobold studied medicine in Homburg (D), Zurich (CH) and Bordeaux (F). He completed his doctoral training in tumor immunology with C. Renner in Zurich and Homburg. Dr. Kobold did his residency training in hematology, oncology and clinical pharmacology in Hamburg and Munich. Since 2014 Dr. Kobold is a board certified clinical pharmacologist and immunologist and serves as attending physician at the university hospital of the LMU. Dr. Kobold trained as a post doctoral fellow in Hamburg (D. Atanackovic), Munich (S. Endres) and Boston (K. Wucherpfennig). In 2019 he was appointed Professor of Medicine and Experimental Immunooncology at the LMU Munich and as deputy director of the division of clinical pharmacology at the University hospital of the LMU. The research of Prof. Kobold is focussed on developing innovative immunotherapeutic strategies utilizing T cells for cancer treatment. His research has been internationally recognized with among others the Ernst-Jung Career Advancement Award, the Vincenz Czerny Award for cancer research, the Johann-Georg-Zimmermann Award for cancer research and more recently the Wilhelm Vaillant Price for Medical Research. Dr. Kobold also serves as senior academic editor to the Journal for the Immunotherapy of Cancer and the European Journal of Cancer and reviews for international leading journals and grant funders including the Nature and Science publishing groups.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kobold, S. (2021, February 1). CAR-T and TCR-T cellular immunotherapies in oncology [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 16, 2026, from https://doi.org/10.69645/YPCI7467.Export Citation (RIS)
Publication History
- Published on February 1, 2021
Financial Disclosures
- Dr. Kobold serves or has served on scientific advisory boards to Celyad SA, TCR2 Inc and Novartis. Dr. Kobold has received honoraria or research support from Regeneron, Miltenyi, Biomedicines, Plectonic, Cymab, GSK, Galapagos, Catalyn, GmBH, Arcus Biosciences, Tabby Therapeutics Ltd, TCR2 Inc, Novartis and BMS. Dr. Kobold holds several patent applications in the immuno-oncology field and has licenced I.P. to TCR2 Inc and Carina Biotech for which he has received licensing fees. He is a shareholder in Adaptimmune.